M
Mark Page
Researcher at National Institute for Biological Standards and Control
Publications - 73
Citations - 1425
Mark Page is an academic researcher from National Institute for Biological Standards and Control. The author has contributed to research in topics: Virus & Vaccination. The author has an hindex of 18, co-authored 65 publications receiving 1044 citations. Previous affiliations of Mark Page include University of Hertfordshire.
Papers
More filters
Journal ArticleDOI
WHO International Standard for anti-SARS-CoV-2 immunoglobulin.
Paul A. Kristiansen,Mark Page,Valentina Bernasconi,Giada Mattiuzzo,Peter Dull,Karen W. Makar,Stanley A. Plotkin,Ivana Knezevic +7 more
Journal ArticleDOI
Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine.
E.J. Stott,F. Taffs,P.A. Kitchin,Woon Ling Chan,Woon Ling Chan,Khg Mills,Khg Mills,Mark Page,Mark Page,Martin Cranage,P. J. Greenaway +10 more
TL;DR: The same vaccination regimen used after live virus challenge did not eliminate virus from previously infected macaques, and virus and proviral DNA were not found in any of the vaccinated animals.
Journal ArticleDOI
WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community.
Ivana Knezevic,Giada Mattiuzzo,Mark Page,Philip D. Minor,Elwyn Griffiths,Micha Nuebling,Vasee S. Moorthy +6 more
TL;DR: The first WHO International Antibody Standards for SARS-CoV-2 immunoglobulin were established by the WHO Expert Committee on Biological Standardization in December 2020 as mentioned in this paper.
Journal ArticleDOI
Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers
Maria-Christina Jung,Norbert H. Grüner,Reinhart Zachoval,W. Schraut,Tilman Gerlach,Helmut M. Diepolder,C.A. Schirren,Mark Page,John R. Bailey,Emma Birtles,Eve Whitehead,Jörg Trojan,Stefan Zeuzem,Gerd R. Pape +13 more
TL;DR: Analysis indicated that this approach does not activate HBV-specific CD8+ T-lymphocytes as detected by ELISPOT-assay, which might explain why a specific therapeutic vaccine, although safe and well-tolerated is not always able to break tolerance leading to the clearance of the hepatitis B virus.
Journal ArticleDOI
Passive immunization of cynomolgus macaques with immune sera or a pool of neutralizing monoclonal antibodies failed to protect against challenge with SIVmac251.
K. Kent,P. Kitchin,Kingston H. G. Mills,Mark Page,Frank Taffs,T. Corcoran,P. Silvera,B. Flanagan,C. Powell,J. Rose,C Ling,A. M. Aubertin,E.J. Stott +12 more
TL;DR: The results suggest that in this model the presence of circulating neutralizing antibodies alone does not necessarily confer protection against challenge with SIVmac251 grown in simian cells.